文献速递新发突发、热带与寄生虫病

类鼻疽新一代诊断:i-STAT卡盒原型检测伯克霍尔德菌生物标志物的评估

Next-generation Diagnostics for Melioidosis: Evaluation of a Prototype i-STAT Cartridge to Detect Burkholderia pseudomallei Biomarkers.
PubMed 文献 · Clin Infect Dis · 2019-01-01

研究开发了基于i-STAT卡盒的原型即时检测方法,利用针对致病性伯克霍尔德菌属荚膜的单克隆抗体,在414份来自澳大利亚和柬埔寨的临床标本中评估。该检测能准确区分澳大利亚血培养阳性类鼻疽患者与其他感染患者(AUC=0.91,95%CI 0.817-1.0),衍生 cutoff 灵敏度76%、特异度94%,正确分类88%(n=74)的澳大利亚患者;但柬埔寨血培养阳性患者仅46%(6/13)被正确分类。检测对血培养阴性类鼻疽患者血标本的荚膜检出率为32%,对尿液、脓液和痰液显示高灵敏度和特异度。

要点

  • i-STAT原型检测可区分澳大利亚血培养阳性类鼻疽患者与其他感染患者,AUC达0.91。
  • 该检测对柬埔寨血培养阳性患者分类正确率仅46%,提示地区差异。
  • 检测可检出部分血培养阴性类鼻疽患者血中的荚膜抗原,对尿液、脓液和痰液敏感。

核心结论

  • 不依赖细菌生长动力学或菌血症水平的诊断工具是类鼻疽下一代诊断方向,需进一步研究。

研究设计与样本

  • 开发基于i-STAT卡盒的原型即时检测,采用针对致病性伯克霍尔德菌属荚膜的单克隆抗体,在414份来自澳大利亚达尔文和柬埔寨的临床标本中评估。

主要发现

  • i-STAT检测准确区分澳大利亚血培养阳性类鼻疽患者与澳大利亚其他感染住院患者,AUC=0.91(95%CI 0.817-1.0)。
  • 衍生 assay cutoff 灵敏度76%、特异度94%,正确分类88%(n=74)的澳大利亚患者。
  • 柬埔寨血培养阳性类鼻疽患者仅46%(6/13)被正确分类。
  • 检测在两组队列中检出32%血培养阴性类鼻疽患者血标本的荚膜,并检出柬埔寨既往未诊断的类鼻疽患者。
  • 检测对尿液、脓液和痰液显示高灵敏度和特异度。

关键数值与推荐

  • 澳大利亚队列区分类鼻疽与其他感染的AUC=0.91(95%CI 0.817-1.0)。
  • 衍生 cutoff 灵敏度76%、特异度94%,正确分类88%(n=74)的澳大利亚患者。
  • 柬埔寨血培养阳性类鼻疽患者正确分类率46%(6/13)。
  • 血培养阴性类鼻疽患者血标本荚膜检出率32%。

临床怎么用

  • 该原型检测有望作为类鼻疽即时诊断工具,尤其对血培养阴性患者和尿液、脓液、痰液标本具有补充价值;但需注意地区间性能差异,柬埔寨血培养阳性患者检出率较低。

局限性

  • 柬埔寨血培养阳性类鼻疽患者分类正确率仅46%,提示检测性能存在地区差异。
  • 检测对血标本的灵敏度受类鼻疽患者菌血症水平低限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infection with the gram-negative bacterium Burkholderia pseudomallei can result in melioidosis, a life-threatening disease that can be difficult to diagnose. Culture remains the gold standard for diagnosis but requires laboratory resources not available in many endemic regions. A lateral flow immunoassay has shown promise for POC diagnostics but suffers from low sensitivity when used on blood samples. PCR also has low sensitivity on blood, attributed to the low bacterial numbers in blood observed in melioidosis patients, even when bacteraemic. METHODS: A prototype i-STAT cartridge was developed to utilize the monoclonal antibody specific for the capsule of pathogenic Burkholderia species employed on the LFI. The resulting POC assay was evaluated on 414 clinical specimens from Darwin, Australia and Cambodia. RESULTS: The i-STAT assay accurately distinguished Australian blood culture positive melioidosis patients from Australian patients hospitalized with other infections (AUC = 0.91, 95% CI 0.817 - 1.0). We derived an assay cutoff with 76% sensitivity and 94% specificity that correctly classified 88% (n = 74) of the Australian patients. Interestingly, only 46% (6/13) of the culture-positive melioidosis patients in Cambodia were classified correctly. Of great importance however, the assay detected capsule from blood samples for 32% of blood culture negative melioidosis patients in both cohorts and previously undiagnosed melioidosis patients in Cambodia. In addition the assay showed high sensitivity and specificity for urine, pus and sputum. CONCLUSIONS: Diagnostic tools that are not dependent upon the growth kinetics or the levels of bacteremia of B. pseudomallei represent the next-generation of diagnostics and must be pursued further.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Schully KL, Young CC, Mayo M, et al. Next-generation Diagnostics for Melioidosis: Evaluation of a Prototype i-STAT Cartridge to Detect Burkholderia pseudomallei Biomarkers. Clin Infect Dis. 2019. PMID: 30403768. doi:10.1093/cid/ciy929

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。